Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FeRiva
- Development stage
- Unknown
- Lead developer
- Avion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FeRiva is a prescription iron supplement launched by Avion Pharmaceuticals on February 26, 2013. It is designed to deliver 75 mg of elemental iron using two forms: Ferrochel (Ferrous Bis-glycinate Sulfate) from Albion Laboratories, Inc. and Ferronyl (Carbonyl Iron) from ISP Investments, Inc. The product utilizes a patented multi-compartment capsule technology, licensed from INNERCAP Technologies, Inc., to improve absorption and tolerability while minimizing gastrointestinal side effects. FeRiva is primarily marketed to the women's health and Ob/Gyn healthcare provider community to address iron deficiency.
- Brand names
- FeRiva
02
Targets
FTL (Ferritin light chain)
Beyond the preview
Go deeper on FeRiva.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FeRiva.